5 drug(s) with this reaction
1,691 total reports
Pulmonary Embolism has been reported as an adverse reaction across 5 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,691 adverse event reports mention pulmonary embolism in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with pulmonary embolism, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have pulmonary embolism listed in their FDA adverse event reports, sorted by report count:
In addition to pulmonary embolism, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
5 drug(s) manufactured by Amgen Inc have pulmonary embolism listed in their FDA adverse event reports: DARBEPOETIN ALFA, PEGFILGRASTIM, FILGRASTIM, ROMIPLOSTIM, PANITUMUMAB.
There are a combined 1,691 reports of pulmonary embolism across 5 Amgen Inc drug(s) in the FDA adverse event database.